Clinical Trial Update: Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing concurrent induction chemoimmunotherapy with epirubicin, oxaliplatin, capecitabine, and panitumumab in KRAS wild-type, resectable Type…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Epirubicin (epirubicin)
• OXALIPLATIN (Oxaliplatin)
• Panitumumab (panitumumab)

Snippet

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Conditions: KRAS Wild Type, Resectable Type II Gastric Adenocarcinoma | Phase 2 | Status: TERMINATED